Received Oct 31, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAPIPV | DTAP + IPV (KINRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | — | — |
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
Vaccine stored outside recommended conditions and administered to patient; This non-serious case was reported by a nurse via call center representative and described the occurrence of incorrect storage of drug in a patient who received Men B NVS (Bexsero) for prophylaxis. Co-suspect products included DTPa (Reduced antigen) (Boostrix) for prophylaxis and DTPa-IPV (Kinrix) for prophylaxis. On an unknown date, the patient received Bexsero, Boostrix and Kinrix. On an unknown date, an unknown time after receiving Bexsero, Boostrix and Kinrix, the patient experienced incorrect storage of drug (Verbatim: Vaccine stored outside recommended conditions and administered to patient). The outcome of the incorrect storage of drug was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 17-OCT-2025 The registered nurse and clinical manager had reported that they experienced a temperature excursion on one of their units on 8 Oct 2025. The vaccines in that fridge had been out of temperature for 45 minutes, reaching a low of negative two degrees Celsius. As per audits, they were required to call the manufacturers. The reporter had enquired whether the vaccines Kinrix, Men B, and Boostrix, if they had been used, would need to be repeated. The batch number was not provided upon follow- up with the reporter.